Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $8.50 Average Price Target from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have earned an average recommendation of “Buy” from the six brokerages that are currently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $8.50.

Several equities research analysts recently weighed in on PYXS shares. Royal Bank of Canada restated an “outperform” rating and set a $7.00 target price on shares of Pyxis Oncology in a research note on Friday, March 22nd. BTIG Research initiated coverage on shares of Pyxis Oncology in a research report on Friday, February 9th. They issued a “buy” rating and a $8.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Pyxis Oncology in a report on Wednesday, April 10th. Leerink Partnrs reissued an “outperform” rating on shares of Pyxis Oncology in a report on Tuesday, January 23rd. Finally, SVB Leerink began coverage on Pyxis Oncology in a research note on Tuesday, January 23rd. They set an “outperform” rating and a $12.00 price target on the stock.

Pyxis Oncology Stock Performance

Pyxis Oncology stock opened at $4.38 on Thursday. The company has a market capitalization of $257.89 million, a price-to-earnings ratio of -2.38 and a beta of 1.45. The company’s 50 day simple moving average is $5.05 and its 200-day simple moving average is $3.33. Pyxis Oncology has a 1 year low of $1.35 and a 1 year high of $6.85.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Thursday, March 21st. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.16. Equities analysts expect that Pyxis Oncology will post -0.85 earnings per share for the current year.

Hedge Funds Weigh In On Pyxis Oncology

Several hedge funds have recently bought and sold shares of the stock. Commonwealth Equity Services LLC purchased a new position in shares of Pyxis Oncology during the third quarter valued at approximately $26,000. Acadian Asset Management LLC purchased a new position in shares of Pyxis Oncology during the 3rd quarter worth $26,000. Schulhoff & Co. Inc. acquired a new stake in shares of Pyxis Oncology during the third quarter worth $44,000. Radcliffe Capital Management L.P. acquired a new stake in shares of Pyxis Oncology during the third quarter worth $106,000. Finally, Cable Car Capital LLC acquired a new position in Pyxis Oncology in the fourth quarter valued at $111,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.